Misrouted cell surface receptors as a novel disease aetiology and potential therapeutic target: The case of hypogonadotropic hypogonadism due to gonadotropin-releasing hormone resistance

Expert Opinion on Therapeutic Targets

Volumn 7, Issue 2, 2003, Pages 175-185

  Ulloa Aguirre, Alfredo ^a,b   Janovick, Jo Ann ^a   Leaños Miranda, Alfredo ^a,b   Conn, Michael ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

G protein coupled receptors; Gonadotropin releasing hormone; Hypogonadotropic hypogonadism; Membrane receptors; Pharmacological chaperones

Indexed keywords

2 [5 [2 (2 AZABICYLO[2.2.2]OCT 2 YL) 1,1 DIMETHYL 2 OXOETHYL] 2 (3,5 DIMETHYLPHENYL) 1H INDOL 3 YL] N (2 PYRIDIN 4 YLETHYL)PROPAN 1 AMINE; CELL SURFACE RECEPTOR; CETRORELIX; ERYTHROMYCIN; GONADORELIN; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; INDOLE DERIVATIVE; LIXIVAPTAN; MACROLIDE; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

CELL PERMEABILIZATION; CELL TRANSPORT; DRUG TARGETING; GENE MUTATION; HORMONE RESISTANCE; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; NONHUMAN; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN SECRETION; PROTEIN TRANSPORT; QUALITY CONTROL; REVIEW;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; AQUAPORIN 2; CELL MEMBRANE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DESIGN; DRUG RESISTANCE; GENES, RECESSIVE; GENETIC DISEASES, INBORN; GONADOTROPIN-RELEASING HORMONE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; HYPOGONADISM; MODELS, MOLECULAR; MOLECULAR CHAPERONES; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POINT MUTATION; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN TRANSPORT; RECEPTORS, CELL SURFACE; RECEPTORS, LHRH; RHODOPSIN; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0242500958     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.7.2.175     Document Type: Review

References (65)

1. CONN PM, CROWLEY WF: Gonadotropin-releasing hormone and its analogues. New Engl. J. Med. (1991) 324:93-103.
2. ULLOA-AGUIRRE A, TIMOSSI C: Biochemical and functional aspects of gonadotropin-releasing hormone and gonadotropins. RBM Online (2000) 1:48-62.
3. ULLOA-AGUIRRE A, MAYA-NÚÑEZ G, SÖDERLUND D, CONN PM: GnRH receptor gene, mutation of. In: Encyclopedia of Endocrinology and Endocrine Diseases. Martini L (Ed.), Academic Press, San Diego (2003). In Press.
4. DE ROUX N, MILGROM E: Inherited disorders of GnRH and gonadotropin receptors. Mol. Cell. Endocrinol. (2001) 179:83-87.
5. SEALFON SC, WEINSTEIN H, MILLAR RP: Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr. Rev. (1997) 18:180-205.
6. ULLOA-AGUIRRE A, CONN PM: G protein-coupled receptors and the G protein family. In: Handbook of Physiology (Section 7) (Vol. I): Cellular Endocrinology. Conn PM (Ed.), Oxford University Press, New York (1998):87-124.
7. LIN X, JANOVICK JA, BROTHERS S, BLÖMENROHR M, BOGERD J, CONN PM: Addition of catfish gonadotropin-releasing hormone (GnRH) receptor intracellular carboxyl-terminal tail to rat GnRH receptor alters receptor expression and regulation. Mol. Endocrinol. (1998) 12:161-171.
8. KOTTLER ML, LORENZO F, BERGAMETTI F, COMMERCON P, SOUCHIER C, COUNIS R: Subregional mapping of the human gonadotropin-releasing hormone receptor (GnRH-R) gene to 4q between markets D4S392 and D4S409. Hum. Genet. (1995) 96:477-480.
9. ULLOA-AGUIRRE A, STANISLAUS D, JANOVICK JA, CONN PM: Structure-activity relationships of G protein-coupled receptors. Arch. Med. Res. (1999) 30:420-435.
10. KOTTLER M-L, COUNIS R, BOUCHARD P: Mutations of the GnRH receptor gene: a new cause of autosomal-recessive hypogonadotropic hypogonadism. Arch. Med. Res. (1999) 30:481-485.
11. RADFORD SE, DOBSON CM: From computer simulations to human disease: emerging themes in protein folding. Cell (1999) 97:291-298.
12. BROOKS DA: Molecular chaperones of the ER: their role in protein folding and genetic disease. Semin. Cell Dev. Biol. (1999) 10:441-442.
13. SANDERS CR, NAGY JK: Misfolding of membrane proteins in health and disease: the lady or the tiger? Curr. Opin. Struct. Biol. (2000) 10:438-442.
14. BELLOTI V, MANGIONE P, STOPPINI M: Biological activity and pathological implications of misfolded proteins. Cell. Mol. Life Sci. (1999) 55:977-991.
15. CAHILL M, CAHILL S, CAHILL K: Proteins wriggle. Biophys. J. (2002) 82:2665-2670.
16. HELENIUS A. Quality control in the secretory assembly line. Phil. Trans. R. Soc. Lond. (2001) 356:147-150.
17. ELLGAARD L, HELENIUS A: Quality control: towards an understanding at the molecular level. Curr. Opin. Cell Biol. (2001) 13:431-437.
18. HARTL FU, HAYER-HARTL M: Molecular chaperones in the cytosol: from nascent chain to folded protein. Science (2002) 295:1852-1858.
19. ELLGAARD L: Setting the standards: quality control in the secretory pathway. Science (1999) 286:1882-1888.
20. MORELLO JP, PETÄJÄ-REPO UE, BICHET DG, BOUVIER M: Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol. Sci. (2000) 21:466-469.
21. LUQUE I, LEAVITT SA, FREIRE E: The linkage between protein folding and functional cooperativity: two sides of the same coin? Ann. Rev. Biophys. Biomol. Struct. (2002) 31:235-256.
22. BRADY AE, LIMBIRD LE: G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction. Cell. Signal. (2002) 14:297-309.
23. DWYER ND, TROEMEL ER, SENGUPTA P, BARGMANN CI: Odorant receptor localization to olfactory cilia is mediated by ODR-4, novel membrane-associated protein. Cell. (1998) 93:455-466.
24. LIU D, BIENKOWSKA J, PETOSA C, COLLIER RJ, FU H, LIDDINGTON R: Crystal structure of the zeta isoform of the 14-3-3 protein. Nature (1995) 376:191-194.
25. SCHNEUWLY S, SHORTRIDGE RD, LARRIVEE DC, ONO T, OZAKI M, PAK WL: Drosophila ninaA gene encodes an eye-specific cyclophilin (cyclosporine A binding protein). Proc. Natl. Acad. Sci. USA (1989) 86:5390-5394.
26. SHIEH BH, STAMNES MA, SEAVELLO S, HARRIS GL, ZUKER CS: The ninaA gene required for visual transduction in Drosophila encodes a homologue of cyclosporin A-binding protein. Nature (1989) 338:67-70.
27. COLLEY NJ, BAKER EK, STAMNES MA, ZUKER CS: The cyclophilin homolog ninaA is required in the secretory pathway. Cell (1991) 67:255-263.
28. BAKER EK, COLLEY NJ, ZUKER CS: The cyclophilin homolog NinaA functions as a chaperone, forming a stable complex in vivo with its protein target rhodopsin. EMBO J. (1994) 13:4886-4895.
29. ROZELL TG, DAVIS DP, CHAI Y, SEGALOFF DL: Association of gonadotropin receptor precursors with the protein folding chaperone calnexin. Endocrinology (1998) 139:1588-1593.
30. MORELLO JP, SALAHPOUR A, PETÄJÄ-REPO UE et al.: Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus. Biochemistry (2001) 40:6766-6775.
31. HOBBS HH, RUSSELL DW, BROWN MS, GOLDSTEIN JL: The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Ann. Rev. Genet. (1990) 24:133-170.
32. WELSH ML, SMITH AE: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell (1993) 73:1251-1254.
33. DENNING GM, ANDERSON MP, AMARA JF, MARSHALL J, SMITH AE, WELSH MJ: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature (1992) 358:761-764.
34. BIRNBAUMER M: Vasopressin receptor mutations and nephrogenic diabetes insipidus. Arch. Med. Res. (1999) 30:465-474.
35. KNOERS NV, DEEN PM: Molecular and cellular defects in nephrogenic diabetes insipidus. Pediatr. Nephrol. (2001) 16:1146-1152.
36. MORELLO JP, BICHET DG: Nephrogenic diabetes insipidus. Ann. Rev. Physiol. (2001) 63:607-630.
37. DRYJA TP, LI T: Molecular genetics of retinitis pigmentosa. Hum. Mol. Genet. (1995) 4:1739-1743.
38. SUNG CH, MAKINO C, BAYLOR D, NATHANS J: A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment. J. Neurosci. (1994) 14:5818-5833.
39. LI T, SNYDER WK, OLSSON JE, DRYJA TP: Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proc. Natl. Acad. Sci. USA (1996) 93:14176-14181.
40. DERETIC D, PULEO-SCHEPPKE B, TRIPPE C: Cytoplasmic domain of rhodopsin is essential for post-Golgi vesicle formation in a retinal cell-free system. J. Biol. Chem. (1996) 271:2279-2286.
41. 90K) GnRH receptor function by a deletion at a distant site. J. Clin. Endocrinol. Metab. (2002) 87:2144-2149.
42. JANOVICK JA, MAYA-NÚÑEZ G, CONN PM: Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J. Clin. Endocrinol. Metab. (2002) 87:3255-3262.
43. PATEL DD, LELLI N, GARUTI R et al.: Analysis of two duplications of the LDL receptor gene affecting intracellular transport, catabolism, and surface binding of the LDL receptor. J. Lipid. Res. (1998) 39:1466-1475.
44. TAMARAPPOO BK, VERKMAN AS: Defective aquaporin-2 trafficking in nephrogenic diabetes insipidus and correction by chemical chaperones. J. Clin. Invest. (1999) 101:2257-2267.
45. SÖDERLUND D, CANTO P, DE LA CHESNAYE E, ULLOA-AGUIRRE A, MÉNDEZ JP: A novel homozygous mutation in the second transmembrane domain of the gonadotropin releasing hormone receptor gene. Clin. Endocrinol. (Oxf.) (2001) 54:493-498.
46. SATO S, WARD CL, KROUSE ME, WINE JJ, KOPITO RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. (1996) 271:635-638.
47. CHENG SH, FANG SL, ZABNER J et al.: Functional activation of the cystic fibrosis trafficking mutant ΔF508-CFTR by overexpression. Am. J. Physiol. (1995) 268:L615-L624.
48. BROWN CR, HONG-BROWN LQ, WELCH WJ: Correcting temperature-sensitive protein folding defects. J. Clin. Endocrinol. Metab. (1997) 99:1432-1444.
49. MATSUDA S, SUZUKI-FUJIMOTO T, MINOWA A, UENO H, KATAMURA K, KOYASU S: Temperature-sensitive ZAP70 mutants degrading through a proteasome-independent pathway. Restoration of a kinase domain mutant by Cdc37. J. Biol. Chem (1999) 274:34515-34518.
50. ZHOU Z, GONG Q, JANUARY CT: Correction of defective protein-trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J. Biol. Chem. (1999) 274:31123-31126.
51. 2 vasopressin receptor mutants. J. Clin. Invest. (2000) 105:887-895.
52. 2 receptor mutants G185C and R202C by a second site suppressor mutation. J. Biol. Chem. (2001) 276:8384-8392.
53. PETÄJÄ-REPO UE, HOGUE M, BHALLA S, LAPERRIÈRE A, MORELLO JP, BOUVIER M: Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. EMBO J. (2002) 21:1628-1637.
54. SUNG CH, SCHNEIDER BG, AGARWAL N, PAPERMASTER DS, NATHANS J: Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. USA (1991) 88:8840-8844.
55. PETÄJÄ-REPO UE, HOGUE M, LAPERRIÈRE A, WALKER P, BOUVIER M: Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human δ opioid receptor. J. Biol. Chem. (2000) 275:13727-13736.
56. PETÄJÄ-REPO UE, HOGUE M, LAPERRIÈRE A, BHALLA S, WALKER P, BOUVIER M: Newly synthesized human δ opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome. J. Biol. Chem. (2001) 276:4416-4423.
57. ASHTON WT, SISCO RM, YANG YT et al.: Potent nonpeptide GnRH receptor antagonists derived from substituted indole-5-carboxamides and -acetamides bearing a pyridine side-chain terminus. Bioorg. Med. Chem. Lett. (2001) 11:1727-1731.
58. ASHTON WT, SISCO RM, YANG YT et al.: Substituted indole-5-carboxamides and -acetamides as potent nonpeptide GnRH receptor antagonists. Bioorg. Med. Chem. Lett. (2001) 11:1723-1726.
59. ASHTON WT, SISCO RM, KIECZYKOWSKI GR et al.: Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. Bioorg. Med. Chem. Lett. (2001) 11:2597-2602.
60. LEAÑOS-MIRANDA A, JANOVICK JA, CONN PM: Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in GnRHR-mediated hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. (2002) 87:4825-4828.
61. LEAÑOS-MIRANDA A, JANOVICK JA, MAYA-NÚÑEZ G, ULLOA-AGUIRRE A, CONN PM: Misrouted proteins as a novel disease etiology and therapeutic target: rescue of hypogonadotropic hypogonadism-causing and manufactured gonadotropin-releasing hormone receptor mutants as a proof of principle. In: Molecular Endocrinology: Methods and Protocols. Kumar R (Ed.), Humana Press, Totowa, New Jersey (2003). In Press.
62. VRECL M, ANDERSON L, HANYALOGLU A et al.: Agonist-induced endocytosis and recycling of the gonadotropin-releasing hormone receptor: effect of β-arrestin on internalization kinetics. Mol. Endocrinol. (1998) 12:1818-1829.
63. MYBURGH DB, PAWSON AJ, DAVIDSON JS, FLANAGAN CA, MILLER RP, HAPGOOD JP: A single amino acid substitution in transmembrane helix VI results in overexpression of the human GnRH receptor. Eur. J. Endocrinol. (1998) 139:438-447.
64. PRALONG FP, GOMEZ F, CASTILLO E et al.: Complete hypogonadotropic hypogonadism associated with a novel inactivating mutation of the gonadotropin-releasing hormone receptor. J. Clin. Endocrinol. Metab. (1999) 84:3811-3816.
65. JANOVICK J, GOULET M, BUSH E, GREER J, WETTLAUFFER D, CONN P.M: Chemical characteristics of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J. Pharmacol. Exp. Ther. (2003). In Press.